Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering CorporationfiledCriticalSchering Corporation
Publication of YU4792ApublicationCriticalpatent/YU4792A/en
Medicines Containing Material From Animals Or Micro-Organisms
(AREA)
Abstract
POSTUPAK GAJENJA TUMORNIH INFILTIRAJUCIH LIMFOCITA, obezbedjen je postupak za korišćenje interleukina-10 u adoptivnoj imunoterapji raka. Populacija tumornih infiltrirajućih limfocita (TIL) i/ili limfokinski aktiviranih ćelija-ubica (LAK) ekspanduje se u kulturi u prisustvu interleukina-2 (IL-2) ili interleukina-10 (IL-10). Nakon davanja TIL i/ili LAK pacijentu, daju mu se i efikasne količine IL-2 i IL-10, kako bi se pojačala citotoksicnost TIL i/ili LAK prema ćelijama tumora i smanjila sporedna dejstva koja se javljaju zbog toga što IL-2 indukuje proizvodnju citokina u ćelijama pacijenta.PROCEDURE FOR CULTIVATION OF TUMOR INFILTING LYMPHOCYTES, a method for the use of interleukin-10 in the adoptive immunotherapy of cancer is provided. The population of tumor infiltrating lymphocytes (TIL) and / or lymphokine-activated killer cells (LAK) is expanded in culture in the presence of interleukin-2 (IL-2) or interleukin-10 (IL-10). Following administration of TIL and / or LAC to a patient, effective amounts of IL-2 and IL-10 are also administered to enhance the cytotoxicity of TIL and / or LAC to tumor cells and to reduce side effects that occur because IL-2 induces cytokine production in patient cells.
YU4792A1991-01-161992-01-16
PROCEDURE FOR CULTIVATION OF TUMOR INFILTING LYMPHOCYTES
YU4792A
(en)
A feasible method for expansion of peripheral blood lymphocytes by culture with immobilized anti-CD3 monoclonal antibody and interleukin-2 for use in adoptive immunotherapy of cancer patients
Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor (s)